A Phase 2 interventional study of Pridopidine and Placebo in Huntington's Disease, sponsored by Prilenia. Completed at 58 sites in 12 countries. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2021-07-19.
Sponsored by Prilenia · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 138 studies in Huntington Disease with a site in United States — 21 open to participants now, 29 under way, 4 of them phase 3. Huntington Disease · United States.
Among the 138 studies in Huntington Disease with a site in United States, this one is the 6th largest by enrollment of the 90 interventional ones that give a count, is one of 4 that started in 2014, is one of 28 in phase 2, and was the 58th registered.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
Browse Huntington Disease studies →21 of the 138 studies in Huntington Disease with a site in United States are open now. Recruiting first, the newest first:
Prilenia · Sites in United States, Belgium, Canada and 9 more countries
Ages 23–65
Leslie Thompson · Sites in United States
Ages 18–65
Novartis Pharmaceuticals · Sites in United States, Argentina, Australia and 24 more countries
Ages 21–70
Skyhawk Therapeutics, Inc. · Sites in United States, Argentina, Brazil and 7 more countries
Ages 25+
The University of Texas Health Science Center at San Antonio · Sites in United States
Ages 18–85
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.
This study: 21 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
138 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 25 · Phase 2 39 · Phase 3 17 · Phase 4 3
First in 1999; this study’s year is marked. 4 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 408 is above the median of 40 across 207 interventional studies indexed under Huntington Disease.
Median enrollment 44 across the 90 interventional studies, 131 across the 48 observational. Of the 99 that completed or were terminated, 36 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
50 of 138 have an industry lead sponsor. The 10 most frequent:
Prilenia is the lead sponsor of 9 studies on the registry; 2 are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 5 (100%) have results posted.
Prilenia has 6 studies filed under Huntington Disease — fewer than ten, so there is no comparison to draw.
9 of the studies in Huntington Disease with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04713982Phase 3Vanderbilt University Medical CenterImpact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease | 2027-06-30 |
| NCT06843252The University of Texas Health Science Center at San AntonioHome-based TDCS (Transcranial Direct Current Stimulation) for Cognitive and Behavioral Symptoms in Huntington's Disease | 2026-12 |
| NCT06475898Huntington Study GroupLongitudinal Endpoint Assessment of Disease Burden in HD | 2026-12 |
| NCT05326451The University of Texas Health Science Center, HoustonHome-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease | 2026-12-31 |
| NCT03233646Duke UniversityRetinal Imaging in Neurodegenerative Disease | 2026-12-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 138 studies in Huntington Disease with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, multinational, randomized, parallel-group, double-blind, placebo-controlled, dose range finding study to compare the efficacy and safety of different doses of pridopidine versus placebo in the treatment of motor impairment in Huntington's Disease (HD).
Originally, the study was designed to assess the effect of pridopidine on motor function at 26 weeks. Due to the recognition that the primary target of pridopidine is the Sigma-1 receptor, the trial was extended from 26 to 52 weeks to evaluate the effect of pridopidine on Total Functional Capacity (TFC). A minimum of 52 weeks are needed for the placebo group to decline and allow a window to assess an effect on TFC (a prespecified endpoint). Approximately 20% of patients completed 26 weeks of the study before IRB approvals for this extension, and did not continue into the 2nd treatment period up to 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Availability and willingness of a caregiver, informant or family member to accompany the patient to the clinic at study, and the suitability of the caregiver should be judged by the Investigator.
Exclusion Criteria:
Patients receiving medications (within the last 6 weeks prior to screening) that have been proven to prolong or who may require such medications during the course of the study such as but not limited to non allowed anti psychotic medications, tricyclic antidepressants and/or Class I antiarrhythmics
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Twice daily
Drug: Pridopidine · Other: Placebo
Twice daily
Drug: Pridopidine · Other: Placebo
Twice daily
Drug: Pridopidine · Other: Placebo
Twice daily
Drug: Pridopidine · Other: Placebo
Twice daily
Other: Placebo
22.5 mg and 45 mg capsules
Also known as: TV7820
Capsules matching drug
Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26
TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.
Time frame: 26 weeks
Number of Patients With Adverse Events
Time frame: 52 weeks
Change From Baseline in Total Functional Capacity (TFC) at Week 52
The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.
Time frame: 52 weeks
| Milestone | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| Started | 82 | 81 | 82 | 81 | 82 |
| Itt | 82 | 81 | 82 | 81 | 82 |
| Fas | 81 | 75 | 79 | 81 | 81 |
| Safety set | 82 | 81 | 82 | 81 | 82 |
| Completed | 70 | 59 | 65 | 67 | 62 |
| Not completed | 12 | 22 | 17 | 14 | 20 |
| Withdrew: Protocol violation | 1 | 1 | 1 | 1 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Noncompliance | 2 | 1 | 1 | 0 | 0 |
| Withdrew: Other | 1 | 5 | 0 | 2 | 3 |
| Withdrew: Adverse event | 5 | 6 | 11 | 11 | 14 |
| Withdrew: Withdrawal by subject | 3 | 9 | 3 | 0 | 3 |
| Milestone | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| Started | 57 | 49 | 54 | 56 | 46 |
| Started treatment in period 2 | 57 | 49 | 52 | 56 | 46 |
| Completed | 52 | 43 | 44 | 53 | 44 |
| Not completed | 5 | 6 | 10 | 3 | 2 |
| Withdrew: Lack of efficacy | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Noncompliance | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 4 | 5 | 1 | 1 |
| Withdrew: Other | 0 | 1 | 0 | 1 | 0 |
| Withdrew: Not treated | 0 | 0 | 2 | 0 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 2 | 0 | 0 |
| Withdrew: Sponsor decision | 0 | 0 | 1 | 0 | 0 |
TMS was defined as the sum of all UHDRS motor domains ratings. The motor section of the UHDRS assesses motor features of Huntington's Disease (HD) with standardized ratings of oculo-motor function, dysarthria, chorea, dystonia, gait, and postural stability. Each of 15 assessments is rated on a scale of 0 (normal) to 4 (marked impairment) for a TMS range of 0-124. Negative change from baseline values indicate improvement.
| score on a scale | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| Change From Baseline in Unified Huntington's Disease Rating Scale-Total Motor Score (UHDRS-TMS) at Week 26 | -4.79 ± 0.99 | -3.37 ± 1.05 | -3.09 ± 1.02 | -4.13 ± 1.00 | -2.74 ± 1.01 |
| Participants | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| Number of Patients With Adverse Events | 62 | 63 | 69 | 71 | 67 |
The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.
| score on a scale | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| Change From Baseline in Total Functional Capacity (TFC) at Week 52 | -0.83 ± 0.20 | 0.04 ± 0.22 | -0.72 ± 0.21 | -0.65 ± 0.20 | -0.59 ± 0.22 |
The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Negative change from baseline indicates worsening.
| score on a scale | Placebo | Pridopidine 45 mg BID |
|---|---|---|
| Change in Total Functional Capacity (TFC) From Baseline in Patients With Early HD (Defined as Patients With TFC>=7) | -1.17 ± 0.22 | -0.01 ± 0.23 |
The TFC is one subscale of the Unified Huntington's Disease Rating Scale (UHDRS), comprising 5 functional domains associated with disability (occupation, finances, domestic chores, activities of daily living, and care level), with scores on each item ranging from 0 to either 2 or 3. The TFC total score is the sum of the 5 TFC items and can range from 0 to 13, with greater scores indicating higher functioning. Responder was defined as a TFC change to Week 52 of TFC\>=0.
| Participants | Placebo | Pridopidine 45 mg BID |
|---|---|---|
| Total Functional Capacity Responder Rate in Early HD | 20 | 30 |
Q-motor assessments were based on the application of force transducers and 3-dimensional position sensors. The reported parameter is the Pro-Sup-Inter-Tap-interval-MN-Hand, measured in seconds. Positive change from baseline indicates worsening.
| seconds | Placebo | Pridopidine 45 mg BID |
|---|---|---|
| Change from baseline to Week 26 | 0.0247 ± 0.0118 | -0.0096 ± 0.0110 |
| Change from baseline to Week 52 | 0.0447 ± 0.0142 | 0.0003 ± 0.0150 |
Collected over 52 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 0/82 (0%) | 0/82 (0%) | 45/82 (54.9%) |
| Pridopidine 45 mg BID | 0/81 (0%) | 8/81 (9.9%) | 49/81 (60.5%) |
| Pridopidine 67.5 mg BID | 0/82 (0%) | 9/82 (11%) | 63/82 (76.8%) |
| Pridopidine 90 mg BID | 1/81 (1.2%) | 9/81 (11.1%) | 57/81 (70.4%) |
| Pridopidine 112.5 mg BID | 1/82 (1.2%) | 9/82 (11%) | 53/82 (64.6%) |
| Event | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 0/82 | 4/81 | 0/82 | 1/81 | 0/82 |
| Head injuryInjury, poisoning and procedural complications | 0/82 | 2/81 | 0/82 | 0/81 | 1/82 |
| Suicide attemptPsychiatric disorders | 0/82 | 1/81 | 0/82 | 1/81 | 2/82 |
| LacerationInjury, poisoning and procedural complications | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Humerus fractureInjury, poisoning and procedural complications | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Hand fractureInjury, poisoning and procedural complications | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| ConcussionInjury, poisoning and procedural complications | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Skull fractureInjury, poisoning and procedural complications | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Blood creatine phosphokinase increasedInvestigations | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Colon cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/82 | 1/81 | 0/82 | 0/81 | 0/82 |
| Event | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID |
|---|---|---|---|---|---|
| FallInjury, poisoning and procedural complications | 17/82 | 16/81 | 21/82 | 13/81 | 16/82 |
| NasopharyngitisInfections and infestations | 7/82 | 14/81 | 12/82 | 13/81 | 15/82 |
| ChoreaNervous system disorders | 1/82 | 4/81 | 13/82 | 3/81 | 7/82 |
| HeadacheNervous system disorders | 8/82 | 7/81 | 7/82 | 11/81 | 8/82 |
| DiarrhoeaGastrointestinal disorders | 9/82 | 9/81 | 11/82 | 11/81 | 10/82 |
| InsomniaPsychiatric disorders | 3/82 | 5/81 | 11/82 | 9/81 | 9/82 |
| FatigueGeneral disorders | 7/82 | 3/81 | 6/82 | 7/81 | 5/82 |
| AnxietyPsychiatric disorders | 2/82 | 6/81 | 6/82 | 7/81 | 5/82 |
| Weight decreasedInvestigations | 3/82 | 4/81 | 3/82 | 3/81 | 7/82 |
| Suicidal ideationPsychiatric disorders | 0/82 | 2/81 | 7/82 | 1/81 | 0/82 |
Intent-to-treat: all patients randomized into the study
| Age, Continuous(years) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| Mean | 50.3 ± 11.34 | 51.9 ± 11.75 | 51.0 ± 11.83 | 51.3 ± 12.69 | 47.5 ± 11.40 | 50.4 ± 11.85 |
| Sex: Female, Male(Participants) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| Female | 40 | 40 | 41 | 43 | 39 | 203 |
| Male | 42 | 41 | 41 | 38 | 43 | 205 |
| Race/Ethnicity, Customized(Participants) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| White | 73 | 75 | 78 | 75 | 77 | 378 |
| Black | 0 | 0 | 1 | 0 | 0 | 1 |
| Asian | 1 | 0 | 0 | 1 | 0 | 2 |
| Other | 0 | 1 | 0 | 1 | 0 | 2 |
| Missing | 8 | 5 | 3 | 4 | 5 | 25 |
| Use of neuroleptics(Participants) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| Yes | 31 | 31 | 32 | 31 | 32 | 157 |
| No | 51 | 50 | 50 | 50 | 50 | 251 |
| CYP2D6 genotype(Participants) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| Poor metaboliser | 1 | 5 | 4 | 2 | 4 | 16 |
| Extensive metaboliser | 72 | 70 | 70 | 74 | 69 | 355 |
| Intermediate metaboliser | 8 | 5 | 8 | 5 | 9 | 35 |
| Ultra-rapid metaboliser | 1 | 1 | 0 | 0 | 0 | 2 |
| Number of Cytosine-Adenosine-Guanine (CAG) Repeats(Number of CAG repeats) | Placebo | Pridopidine 45 mg BID | Pridopidine 67.5 mg BID | Pridopidine 90 mg BID | Pridopidine 112.5 mg BID | Total |
|---|---|---|---|---|---|---|
| Mean | 44.4 ± 3.23 | 44.1 ± 4.12 | 45.0 ± 4.73 | 44.5 ± 4.90 | 45.3 ± 3.66 | 44.7 ± 4.18 |
Ran from Feb 2014 to primary completion in Dec 2015, 21 months.
Results were first posted in Jul 2021, 5 years 7 months after primary completion. A results delay was requested in May 2018.
Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 21 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pridopidine
Prilenia